"","Blank 1","Frequency","Blank 2","Frequency"
"40","patients who are receiving cyclosporine tacrolimus or other agents to prevent graft versus host disease post bone marrow",7,"                                                                                                       ",11
"1","stem cell",4,"are not eligible for this trial                                                                                  ",7
"2","prior liver",2,"sct patients are eligible 6 weeks after date of autologous stem cell infusion following myeloablative therapy timed from first day of protocol therapy patients are not eligible post allogeneic stem cell transplant patients who have received an autologous stem cell infusion to support non myeloablative therapy such as 131 iodine i mibg are eligible at any time as long as they meet the other criteria for eligibility                                     ",1
"3","step ii patients must not have received any non protocol therapy outside of the assigned induction therapy including stem cell",1,"sct / mibg immunotherapy radiotherapy and retinoids but may not have received second line chemotherapy for resistant / refractory relapsed disease or progressive disease                                                                      ",1
"4","patients must have received frontline therapy including surgery chemotherapy autologous stem cell",1,"patients all patients undergoing planned allogeneic transplant both malignant and non malignant diagnoses                                                                                             ",1
"5","",1,"allogeneic or autologous stem cell rescue during the 3 month study period                                                  ",1
"6","oncology patients patients with an oncology diagnosis that are or will be on a chemotherapy regimen that will last for an additional > = 3 months or are on or will be on a chemotherapy regimen for < 3 months and then proceed to",1,"or have primary refractory disease no upper limit for number of prior therapies if status post allogeneic stem cell transplant no active graft versus host disease                                                               ",1
"7","patients must have relapsed after first line chemotherapy may have relapsed after autologous or allogeneic stem cell",1,"or have primary refractory disease no upper limit for number of prior therapies patient must not have received a prior allogeneic stem cell transplant                                                            ",1
"8","randomized phase ii arms k and l patients must have relapsed after first line chemotherapy may have relapsed after autologous stem cell",1,"or autologous transplant however patients with prior allogeneic bone marrow transplant will be eligible only if both of the following conditions are met the transplant must have been performed > = 90 days prior to registration the patient must not have > = grade 2 acute graft versus host disease gvhd or either moderate or severe limited chronic gvhd within 14 days prior to registration                                   ",1
"9","patients may have received prior allogeneic",1,"at time of registration is not on immunosuppressive therapy to treat / prevent graft versus host disease has no evidence of active graft versus host disease and no evidence of active infection                                                           ",1
"10","allogeneic stem cell transplantation is allowed provided the patient is > = 1 year from",1,"for non aml condition ex . mds mpn lymphoid malignancy aplastic anemia requiring ongoing use of immunosuppressants                                                                               ",1
"11","active graft versus host disease gvhd following allogeneic stem cell",1,"or stem cell infusion                                                                                ",1
"12","stem cell infusion without tbi no evidence of active graft vs host disease and at least 84 days must have elapsed after",1,"or rescue patient has not had a prior stem cell transplant or rescue                                                                                           ",1
"14","prior autologous and / or allogeneic",1,"is permitted although transplant must have occurred greater than 90 days prior to registration                                                                                      ",1
"15","patients must not be candidates for allogeneic hematopoietic stem cell",1,"note subjects up to age 70 years who are considered fit for allogeneic hematopoietic stem cell transplant should be considered for enrollment on e1910 in order to avoid competing with that study if a patient is considered unfit for intensive chemotherapy at the time of initial diagnosis but subsequently achieves a complete remission cr then it will be left to the treating physicianï s discretion to consider hematopoietic stem cell transplant hsct                        ",1
"16","patient is not a candidate for stem cell",1,"due to advanced age or co morbidities or the enrollee does not have donor available or the enrollee declines stem cell transplant due to personal belief or stem cell transplant is not standard of care based on the risk category of disease                                                        ",1
"17","patients with history of organ",1,"hsct for any disease with any graft and any conditioning regimen with at least one manifestation secondary to fibrosis including sclerodermatous skin changes dry mouth dry eye esophageal strictures or vaginal gvhd                                                              ",1
"18","patients with chronic gvhd diagnosed within 3 years after hematopoietic stem cell",1,"prior to enrollment                                                                                         ",1
"19","patient must be > = 12 weeks since autologous bone marrow / stem cell",1,"prior to enrollment > = 5 years since allogeneic bone marrow transplant prior to enrollment with no evidence of active graft versus vs . host disease                                                             ",1
"20","inclusion criteria for stratum c patient must be > = 12 weeks since autologous bone marrow / stem cell",1,"within previous 3 months prior to initiation of study therapy                                                                                              ",1
"22","current candidacy for a potentially curative allogeneic stem cell",1,"unless declined                                                                                               ",1
"23","chl cohort only history of allogeneic",1,"center                                                                                       ",1
"24","patient must be deemed eligible to proceed with high dose chemotherapy and autologous stem cell transplantation by local",1,"if indicated for histology i . e diffuse large b cell lymphoma or autologous stem cell transplant is not feasible                                                                  ",1
"25","alk alcl patients must have disease that has relapsed and or is refractory to prior therapy which must have included a multiagent chemotherapy regimen including an anthracycline if not contraindicated and prior brentuximab prior crizotinib or other alk inhibitor therapy while recommended is not mandatory patients must have relapsed following or be ineligible for or refuse autologous stem cell",1,"sct no evidence of active graft vs . host disease for at least 4 weeks for allogeneic sct patients > = 3 months must have elapsed since transplant must have received no more than 1 prior autologous or allogeneic stem cell transplant . patients must be off all systemic immunosuppressive therapy for at least 2 weeks excluding hydrocortisone for physiologic cortisol replacement                                          ",1
"26","mcl patients must have disease that has relapsed and or is refractory to prior therapy which must have included a multiagent chemotherapy regimen and prior ibrutinib or other btk inhibitor therapy patients must have relapsed following or be ineligible for or refuse autologous stem cell",1,"patients who have received allogeneic hematopoietic stem cell transplant are eligible if the transplant occurred at least 90 days prior to registration patient has no prior acute graft versus host disease gvhd and within 48 hours of registration patient demonstrates at least 90 engraftment defined as anc anc > = 500 mcL measured over 3 consecutive days or 1 day with an anc > = 1 000 mcL or Platelets > = 50 000 mcL measured wherein the patient did not receive any Platelets transfusions within 7 days prior to laboratory assessment",1
"27","bcl6 dlbcl patients must have disease that has relapsed and or is refractory to prior therapy which must have included an anthracycline if not contraindicated patients must have relapsed following or be ineligible for or refuse autologous stem cell",1,"related immunosuppression for at least 2 weeks                                                ",1
"28","aids related non hodgkin lymphoma and other non hodgkin lymphoma failed standard first line therapy and failed autologous stem cell",1,"including cardiac renal liver and pulmonary requirements                                                                                          ",1
"30","patients are not eligible if they have had or are planned for solid organ",1,"or any stem cell infusion including donor lymphocyte infusion dli or boost infusion > = 84 days after infusion and no evidence of graft versus host disease gvhd autologous stem cell infusion including boost infusion > = 42 days                                                 ",1
"31","must not have received any prior stem cell",1,"and have no evidence of active graft versus host disease and are off systemic immunosuppressant medications for at least 2 months and have received hypomethylating agents hma therapy before or after transplant and meet other eligibility criteria of progression after at least 4 months of dnmti therapy are eligible to be enrolled in this clinical trial                                          ",1
"32","no evidence of active graft versus vs . host disease and > = 2 months must have elapsed since",1,"that requires use of immunosuppressives                                                                                             ",1
"33","patients with a history of allogeneic hematopoietic stem cell transplantation hsct will be eligible if they are more than 90 days removed from the date of stem cell infusion have no evidence of acute graft versus host disease gvhd or active chronic grade 2 4 gvhd and are off of all",1,"patients who are receiving cyclosporine tacrolimus or other agents to prevent graft versus host disease post bone marrow transplant are not eligible for this trial                                                                             ",1
"34","donor lymphocyte infusion within 8 weeks prior to treatment start if post",1,"or organ rejection post transplant are not eligible for this trial                                                                            ",1
"35","patients must meet institutional eligibility requirements for stem cell",1,"patients who are receiving cyclosporine tacrolimus or other agents to prevent either graft versus host disease post bone marrow transplant or organ rejection post transplant are not eligible for this trial at least 3 half lives must have elapsed after the last dose of gvhd medications meds                                                  ",1
"36","stem cell infusions with or without total body irradiation tbi allogeneic non autologous bone marrow or stem cell",1,"",NA
"37","patients who relapsed 6 months after bone marrow",1,"",NA
"38","patients must not have any history of organ",1,"",NA
"43","anti gvhd agents post",1,"",NA
"45","patients who are receiving cyclosporine tacrolimus or other agents to prevent either graft versus host disease post bone marrow",1,"",NA
"47","anti gvhd or agents to prevent organ rejection post",1,"",NA
